Company intelligence / Profile preview
Rigerna Therapeutics
Beijing, Beijing Shi, Chinarigerna.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Rigerna has launched Phase 1 trial dosing for RG002 (C3-siRNA) for IgA nephropathy. The company has also completed Proof-of-Concept experiments for its proprietary kidney-targeting siRNA platform in Non-human Primates.
- Therapeutic areas
- Metabolic DisordersNephrology
- Modalities
- siRNARNA interference (RNAi)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Beijing Institute of Technology
Beyond the preview
Go deeper on Rigerna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rigerna Therapeutics.